← Aldeyra Therapeutics, Inc. (ALDX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Aldeyra Therapeutics, Inc. (ALDX)
Pharmaceutical Preparations · market cap $81M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
16
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Aldeyra Therapeutics (ALDX) is a small-cap ophthalmology/dermatology biotech with 8 employees and a ~$125M market cap, built around reproxalap, a reactive aldehyde species (RASP) modulator in late-stage trials for allergic conjunctivitis, dry eye, and Sjögren-Larsson syndrome. The company holds ~$65M in cash with an ~38-month runway and has no disclosed revenue, funding itself entirely through equity. The next formal catalyst is an August 6, 2026 earnings report.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Reproxalap Ophthalmic Solution (0.5%) | Phase 3 | Allergic Conjunctivitis |
| ADX-102 Ophthalmic Drops (0.5%) | Phase 2 | Conjunctivitis, Allergic |
| ADX-2191 | Phase 2 | Retinitis Pigmentosa |
| ADX-629 | Phase 2 | Ethanol Intoxication |
| ADX-629 (Open-label) | Phase 2 | Atopic Dermatitis |
| Xiidra® (5% lifitegrast ophthalmic solution) | Phase 2 | Dry Eye |
| NS2 Ophthalmic Drops (0.5%) | Phase 2 | Allergic Conjunctivitis |
| ADX-102 1% Topical Dermal Cream (reproxalap) | Phase 3 | Sjogren-Larsson Syndrome |
| Active topical NS2 1% dermatologic cream | Phase 2 | Sjögren-Larsson Syndrome |
| NS2 | Phase 2 | Non-infectious Anterior Uveitis |
| ADX-2191 (intravitreal methotrexate 0.8%) | Phase 3 | Proliferative Vitreoretinopathy |
| Reproxalap Ophthalmic Solution (0.1%) | Phase 2 | Dry Eye Syndrome |
| Reproxalap Ophthalmic Solution (0.25%) QID | Phase 3 | Dry Eye |
| Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID | Phase 3 | Dry Eye |
| ADX-102 Ophthalmic Solution (0.5%) | Phase 3 | Dry Eye Syndromes |
| Reproxalap Ophthalmic Solution (0.25%) | Phase 3 | Dry Eye Syndromes |
Price & technical context
3-month
-43.2%
6-month
-23.2%
12-month
-75.3%
52-wk range
$1.16–$5.74
vs 50-day MA
-12.2%
vs 200-day MA
-52.1%
Realized vol
149.9%
Max drawdown
-83.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALDX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.